However, these encouraging trends coexist with areas where clinical practice still falls short of current evidence, particularly in the early recognition of heart failure and consistent adoption of SGLT2 inhibitors in CKD without proteinuria. This evidence concerns the gene SLC5A2 and chronic kidney disease.